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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2005.05.041Objective: In pulmonary neuroendocrine tumors the realization that the extent of
nodal disease is related to cell type has led to a controversy as to which is the domi-
nant prognostic factor, stage or morphology. To clarify this relationship, we studied
patients treated at our institution over a 23-year period.
Methods: This is a historical cohort study of patients with confirmed pulmonary
neuroendocrine tumors who underwent lung resection from 1980 through 2003.
Survivors were contacted by telephone, and recurrences were confirmed by means
of histopathology. Cox proportional hazards regression was used to ascertain the
joint influence of several risk factors on survival.
Results: The mean age of the cohort was 54 years (standard deviation, 15 years), and
100 (57%) were men. The cell types for the 177 eligible patients were typical
carcinoid in 89 (50%), atypical carcinoid in 15 (8%), large cell in 22 (13%), and
small cell in 51 (29%). The median time to follow-up was 7 years (first to third
quartile, 2-12 years), and overall 5- and 10-year survivals were 86% (79%-90%) and
81% (74%-87%), respectively. The univariable predictors of survival were age (P
.001), nodal stage (P  .01), and cell type (P  .001). In the final multivariable
model only age (P  .04) and cell type (P  .001) remained as independent
predictors. The hazard of death among patients with large cell or small cell lung
cancer was highest in the first year and a half after diagnosis, reducing drastically
thereafter.
Conclusions: In pulmonary neuroendocrine tumors cell type is the predominant
determinant of survival. The survival of patients with each cell type is sufficiently
diverse to warrant different management strategies. Conservative resection is fea-
sible for typical carcinoids, but the effects of adjuvant chemotherapy need to be
evaluated for the other subgroups.
The 2004 World Health Organization/International Association for the Studyof Lung Cancer classification for lung tumors recognizes 4 main categoriesof neuroendocrine tumor, namely typical carcinoid (TC), atypical carcinoid
(AC), large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma
(SCLC). These categories are based on varying degrees of differentiation toward a
neuroendocrine phenotype and differences in clinical behavior that warrant different
management strategies.1 Although this classification is predominantly morphologic,
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differentiation within the neuroendocrine phenotype. There
are many articles describing prognosis in relation to these
tumor types,2-5 although there are very few studies that
cover the entire spectrum of neuroendocrine tumors and
look at factors that influence prognosis.6 Furthermore, there
are few data on the effect of systematic nodal dissection
within the 4 subgroups of tumors. The purpose of this study
is therefore to retrospectively review resected tumors of
neuroendocrine phenotype and assess the influence on sur-
vival of disease extent versus both clinical and pathologic
parameters.
Methods
A review was undertaken of patients who underwent surgical inter-
vention for TC, AC, LCNEC, and SCLC between 1980 and 2003 at
the Brompton Hospital. Cases were identified from the pathology
TABLE 1. Baseline characteristics by cell type
Typical
carcinoid
Atypical
carcinoid LCNEC SCLC
N 89 15 22 51
Mean age, y (SD) 48 (15) 58 (10) 63 (10) 61 (11)
Men, n (%) 41 (46) 6 (40) 17 (77) 27 (53)
T category
N/A* 0 (0) 0 (0) 3 (14) 2 (4)
T1 45 (51) 10 (67) 5 (23) 16 (31)
T2 42 (47) 5 (33) 12 (55) 31 (61)
T3 1 (1) 0 (0) 2 (9) 1 (2)
T4 1 (1) 0 (0) 0 (0) 1 (2)
N category
N/A* 1 (1) 0 (0) 3 (14) 2 (4)
N0 75 (84) 8 (53) 9 (41) 18 (35)
N1 11 (12) 3 (20) 6 (27) 21 (41)
N2 2 (2) 4 (27) 4 (18) 10 (20)
Stage
N/A* 1 (1) 0 (0) 3 (13) 2 (4)
I 70 (79) 7 (47) 9 (41) 21 (41)
II 15 (17) 3 (20) 5 (23) 17 (33)
III 2 (2) 4 (27) 4 (18) 11 (22)
IV 1 (1) 1 (7) 1 (5) 0 (0)
Operation, n (%)
Pneumonectomy 4 (4) 3 (20) 1 (5) 26 (51)
Lobectomy 65 (73) 10 (67) 18 (82) 22 (43)
Bilobectomy 6 (7) 1 (7) 1 (5) 2 (4)
Segmentectomy 10 (11) 0 (0) 2 (9) 1 (2)
Nonanatomic 4 (4) 1 (7) 0 (0) 0 (0)
Sleeve resections 30 (34) 3 (20) 0 (0) 0 (0)
No. of deaths (%) 3 (3) 5 (33) 4 (18) 19 (37)
Proportions might not sum to 100% in every category because of rounding.
LCNEC, Large cell neuroendocrine carcinoma; SCLC, small cell lung can-
cer; SD, standard deviation; N/A, not available. Numbers in parentheses
are percentages. *Unable to extract the exact information from all avail-
able data.archive up until 1999 and from a prospective lung cancer resection
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(A.G.N.) and classified according to current histologic criteria for
neuroendocrine tumors.1 We excluded patients if neuroendocrine
tumor was not the confirmatory diagnosis, if the neuroendocrine
tumor was not of pulmonary origin, and if patients did not undergo
anatomic lung resection (bronchoplastic or wedge resection). All
included patients undergoing surgical intervention for AC, LCNEC,
and SCLC underwent systematic node dissection, whereas those
undergoing resection for TC had a more limited nodal dissection. All
cases were staged according to the fifth International Union Against
Cancer revision.7 Some patients with carcinoid tumors have been
reported on previously in a series on the feasibility of resection, 5 and
some with LCNEC have been reported on previously in a series on
staging and prognosis within this subgroup. 8
Data Acquisition
Individual patient data were collated from a prospective histopa-
thology database, patients’ case notes, and autopsy reports. Mor-
tality was determined by using the National Health Service stra-
tegic tracing system, and survivors were contacted by telephone
for interview.
Statistical Analysis
Categoric data are presented as frequency (percentage) and con-
tinuous data as mean with standard deviation or median with first
and third quartiles. Probabilities of survival were estimated by
using the Kaplan-Meier method. Cox proportional hazards regres-
sion models were used to ascertain the association between indi-
vidual factors and survival. Their joint effect was assessed in a
multivariable Cox model in which the criterion for retention of
individual variables was a P value of less than .1. The model’s
assumption of constant hazard ratios over the entire follow-up was
assessed by using the Schoenfeld test.9 When violated, separate
hazard ratios were estimated over different time intervals.
Results
From January 1, 1980, to January 1, 2003, a total of 199
patients underwent surgical intervention with a presumed
diagnosis of neuroendocrine tumor. In total, 5 patients were
excluded when histologic review excluded a neuroendo-
crine tumor, 1 patient was excluded because the tumor was
metastatic to the lung, 14 patients did not undergo anatomic
lung resection, and 2 patients had insufficient data within
hospital records. This left 177 patients as a cohort for the
study.
The mean age of the cohort was 54 years (standard
deviation, 15 years), and 100 (57%) were men. Of 177
patients, histologic review resulted in a diagnosis of TC in
89 (50%), AC in 15 (8%), LCNEC in 22 (13%), and SCLC
in 51 (29%).
Baseline characteristics, stage, and operation extent are
summarized separately by cell type in Table 1. Overall,
patients with LCNEC and SCLC were older, and there was
a greater predominance of male subjects among these pa-
tients. The incidence of nodal disease and its extent was also
greater in these cell types (P  .001). Cell type was also
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less conservative with more aggressive cell type (P  .01).
The median time to follow-up was 7 years (first to third
quartile, 2-12 years), and overall survivals at 5 and 10 years
were 86% (95% confidence interval, 79%-90%) and 81%
(95% confidence interval, 74%-87%), respectively. The
strong association of both cell type and nodal disease with
survival is evident from the Kaplan-Meier plots shown in
Figures 1 and 2.
The effects of age, cell type, T category, N category, and
overall stage on recurrence-free survival were estimated by
using Cox proportional hazards regression (Table 2). For
every 10-year increase in age, there is an estimated 67%
increase in the hazard of recurrence or death. Sex had no
influence on survival. The hazards of death for patients with
ACs and LCNECs were approximately 7-fold those of pa-
tients with TCs, whereas patients with SCLCs had an ap-
Figure 1. Overall survival by cell type. LCNEC, Large cell neu-
roendocrine carcinoma; SCLC, small cell lung cancer.Figure 2. Overall survival by nodal status.
The Journal of Thoraciproximately 15-fold increase in the risk of death compared
with patients with TCs. Increased risk was also associated
with advancing T and N categories. When jointly modeled,
however, only increasing age and cell type were identified
as independent predictors of mortality (Table 3).
The risk of death after surgical intervention for the 2
more aggressive cell types (LCNEC and SCLC) were not
proportional over time (P  .03). Therefore separate hazard
ratios were estimated for the first 1.5 years after surgical
TABLE 2. Univariable risk factors for death
Hazard
ratio
95% confidence
interval P value
Age, per decade 1.67 1.22-2.30 .001
Female sex 0.57 0.27-1.22 .15
Cell type .001*
Typical carcinoid 1
Atypical carcinoid 6.68 1.56-28.61 .01
LCNEC 6.85 1.52-30.73 .01
SCLC 14.70 4.34-49.80 .001
T category .23*
T1 1
T2 1.75 0.79-3.91 .17
T3 2.56 0.32-20.44 .38
T4 8.93 1.11-71.46 .04
N category .01*
N0 1
N1 3.29 1.47-7.40 .004
N2 2.18 0.78-6.17 .14
Overall stage† .07*
I 1
II 2.59 1.12-6.02 .03
III 2.72 1.01-7.30 .05
LCNEC, Large cell neuroendocrine carcinoma; SCLC, small cell lung
cancer. *P value for the overall effect of the category obtained from the
likelihood ratio test. †There were no deaths in the 2 patients with stage IV
disease.
TABLE 3. Multivariable risk factors for recurrence or death
Adjusted hazard
ratio
95% confidence
interval P value
Age, per 10-year
increase
1.51 1.02-2.20 .04
Cell type
Typical carcinoid 1
Atypical carcinoid 3.5 0.99-12.82 .05
LCNEC 1.5 y* 12.51 1.96-79.81 .008
LCNEC 1.5 y† 1.39 0.16-12.45 .76
SCLC 1.5 y* 19.60 4.03-95.32 .001
SCLC 1.5 y† 4.08 1.16-14.34 .03
LCNEC, Large cell neuroendocrine carcinoma; SCLC, small cell lung
cancer. *Adjusted hazard ratio for the time frame immediately after sur-
gical intervention but less than 1.5 years. †Adjusted hazard ratio after
1.5 years since surgical intervention.
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chosen because it corresponded to the time when 50% of
events had occurred.10 The results show that the age-ad-
justed effect of LCNEC and SCLC relative to TC is mainly
restricted to the first 1.5 years since surgical intervention,
reducing drastically thereafter (Table 3), whereas that of AC
was constant over time.
Discussion
The optimum management strategy is not yet defined across
the spectrum of neuroendocrine tumors. The good prognosis
associated with TC allows lung-conserving operations to be
the principle treatment modality in this subgroup,5 whereas
surgical intervention or combined modality treatment forms
the mainstay of therapy for SCLC.11 Less is known about
the optimum management of AC and LCNEC because of
the comparative rarity of these tumor types and their rela-
tively recent acceptance as specific subgroups of neuroen-
docrine tumors.
Influence of Stage and Cell Type
The malignant potential of carcinomas is governed by stage
(extent of disease) and, to a lesser extent, by grade (reflected
by cell type). A knowledge as to which factor predominates
could influence decisions on best therapy. If the prognosis
of a tumor is governed mainly by the extent of the disease,
then complete resection should be the principle aim. How-
ever, if prognosis is independent of stage and determined
predominantly by cell type, then complete resection alone
might be inadequate. The result of our study revealed the
close association between progressive stage and more ag-
gressive cell type. We attempted to differentiate between the
2 influences, showing cell type to be the stronger determi-
nant. This is consistent with a previous study from Martini
and colleagues.3
Clinical Implications
Because our data suggest that cell type is the stronger
determinant of mortality, complete resection alone might be
inadequate for any cell type other than TC, and prospective
trials evaluating the survival with adjuvant chemotherapy
for AC and LCNEC are needed.8
Potential Limitations
To ascertain the features associated with death, we have
included patients with LCNEC and large cell carcinomas
with neuroendocrine morphology in one group in this study.
This is necessary because of the small numbers of such
cases but justified by the lack of a clear difference in clinical
management between the 2 subtypes.
Like most studies on pulmonary neuroendocrine tumors,
we have been limited by the relatively small sample size
972 The Journal of Thoracic and Cardiovascular Surgery ● Octobecause of the rarity of these tumors and the small number
of deaths. Hence it is difficult to compare our results with
those of other studies, especially in the subgroups with
small numbers, because discrepancies in survival can arise
from statistical variation rather than true differences. The
point estimates of our hazard ratios have wide confidence
intervals, reflecting the uncertainly posed by the sample
size limitations.
Although not specifically designed for this purpose, we
applied the International Union Against Cancer/American
Joint Committee on Cancer staging system to neuroendo-
crine tumors, as is widely used in this context, and provided
a means for comparing stage-adjusted survival.
Conclusions
In pulmonary neuroendocrine tumors cell type is the pre-
dominant determinant of survival. The survival of each cell
type is sufficiently diverse to warrant different management
strategies. Surgical treatment by means of parenchyma-
preserving resection is the optimum treatment for TC, but
the effects of adjuvant chemotherapy need to be evaluated
in randomized controlled studies for all other subgroups.
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